Johnson & Johnson revealed data from a phase 1b trial showing 100% objective response in relapsed/refractory large B-cell lymphoma patients with one prior therapy following treatment with a dual CD19/CD20 CAR-T. The therapy demonstrated high efficacy with a promising safety profile, indicating a potential breakthrough in durable cancer remission.